These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 3100576)
41. Prevention of neuropathology in the mouse model of Hurler syndrome. Desmaris N; Verot L; Puech JP; Caillaud C; Vanier MT; Heard JM Ann Neurol; 2004 Jul; 56(1):68-76. PubMed ID: 15236403 [TBL] [Abstract][Full Text] [Related]
43. A nonpathologic allele (IW) for low alpha-L-iduronidase enzyme activity vis-a-vis prenatal diagnosis of Hurler syndrome. Whitley CB; Gorlin RJ; Krivit W Am J Med Genet; 1987 Sep; 28(1):233-43. PubMed ID: 3118714 [TBL] [Abstract][Full Text] [Related]
44. Recombinant encapsulated cells overexpressing alpha-L-iduronidase correct enzyme deficiency in human mucopolysaccharidosis type I cells. Baldo G; Quoos Mayer F; Burin M; Carrillo-Farga J; Matte U; Giugliani R Cells Tissues Organs; 2012; 195(4):323-9. PubMed ID: 21778683 [TBL] [Abstract][Full Text] [Related]
45. Canine alpha-L-iduronidase deficiency. A model of mucopolysaccharidosis I. Shull RM; Munger RJ; Spellacy E; Hall CW; Constantopoulos G; Neufeld EF Am J Pathol; 1982 Nov; 109(2):244-8. PubMed ID: 6215865 [No Abstract] [Full Text] [Related]
46. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Lutzko C; Kruth S; Abrams-Ogg AC; Lau K; Li L; Clark BR; Ruedy C; Nanji S; Foster R; Kohn D; Shull R; Dubé ID Blood; 1999 Mar; 93(6):1895-905. PubMed ID: 10068662 [TBL] [Abstract][Full Text] [Related]
47. [Bone marrow transplantation in mucopolysaccharidosis type I, Hurler-Scheie variety. Metabolic correction and clinical results]. Ortega Aramburu JJ; Domínguez Luengo C; Olivé Oliveras T; Navarro Fernández C An Esp Pediatr; 1990 Oct; 33(4):369-75. PubMed ID: 2126172 [TBL] [Abstract][Full Text] [Related]
49. Mucopolysaccharidosis type I subtypes. Presence of immunologically cross-reactive material and in vitro enhancement of the residual alpha-L-iduronidase activities. Schuchman EH; Desnick RJ J Clin Invest; 1988 Jan; 81(1):98-105. PubMed ID: 3121676 [TBL] [Abstract][Full Text] [Related]
50. Bone marrow transplantation has a significant effect on enzyme levels and storage of glycosaminoglycans in tissues and in isolated hepatocytes of mucopolysaccharidosis type VII mice. Poorthuis BJ; Romme AE; Willemsen R; Wagemaker G Pediatr Res; 1994 Aug; 36(2):187-93. PubMed ID: 7970933 [TBL] [Abstract][Full Text] [Related]
51. Clinical and pathological characterization of ophthalmic disease in a canine model of mucopolysaccharidosis type I. Nenninger A; Ben-Shlomo G; Allbaugh R; Valentine B; Snella E; Jens J; Ellinwood NM; Smith J J Inherit Metab Dis; 2023 Mar; 46(2):348-357. PubMed ID: 36601751 [TBL] [Abstract][Full Text] [Related]
52. Increased longevity and metabolic correction following syngeneic BMT in a murine model of mucopolysaccharidosis type I. Wolf DA; Lenander AW; Nan Z; Braunlin EA; Podetz-Pedersen KM; Whitley CB; Gupta P; Low WC; McIvor RS Bone Marrow Transplant; 2012 Sep; 47(9):1235-40. PubMed ID: 22179554 [TBL] [Abstract][Full Text] [Related]
53. Delivery of recombinant gene product to canine brain with the use of microencapsulation. Barsoum SC; Milgram W; Mackay W; Coblentz C; Delaney KH; Kwiecien JM; Kruth SA; Chang PL J Lab Clin Med; 2003 Dec; 142(6):399-413. PubMed ID: 14713892 [TBL] [Abstract][Full Text] [Related]
54. Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Kobayashi H; Carbonaro D; Pepper K; Petersen D; Ge S; Jackson H; Shimada H; Moats R; Kohn DB Mol Ther; 2005 May; 11(5):776-89. PubMed ID: 15851016 [TBL] [Abstract][Full Text] [Related]
55. 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment. Gabrielli O; Clarke LA; Ficcadenti A; Santoro L; Zampini L; Volpi N; Coppa GV BMC Med Genet; 2016 Mar; 17():19. PubMed ID: 26965916 [TBL] [Abstract][Full Text] [Related]
56. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Hartung SD; Frandsen JL; Pan D; Koniar BL; Graupman P; Gunther R; Low WC; Whitley CB; McIvor RS Mol Ther; 2004 Jun; 9(6):866-75. PubMed ID: 15194053 [TBL] [Abstract][Full Text] [Related]
57. The relationship of alpha-L-iduronidase and Hurler corrective factor. Shapiro LJ; Hall CW; Leder IG; Neufeld EF Arch Biochem Biophys; 1976 Jan; 172(1):156-61. PubMed ID: 3136 [No Abstract] [Full Text] [Related]
58. Absence of alpha-L-iduronidase activity in various tissues from two sibs affected with presumably the Hurler-Scheie compound syndrome. Thompson JN; Finley SC; Lorincz AE; Finley WH Birth Defects Orig Artic Ser; 1975; 11(6):341-6. PubMed ID: 811284 [No Abstract] [Full Text] [Related]
59. Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice. Baldo G; Mayer FQ; Martinelli BZ; de Carvalho TG; Meyer FS; de Oliveira PG; Meurer L; Tavares A; Matte U; Giugliani R Mol Genet Metab; 2013 May; 109(1):33-40. PubMed ID: 23562162 [TBL] [Abstract][Full Text] [Related]
60. The defect in the Hurler and Scheie syndromes: deficiency of -L-iduronidase. Bach G; Friedman R; Weissmann B; Neufeld EF Proc Natl Acad Sci U S A; 1972 Aug; 69(8):2048-51. PubMed ID: 4262258 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]